P
Paramita Sen
Researcher at Novartis
Publications - 12
Citations - 1150
Paramita Sen is an academic researcher from Novartis. The author has contributed to research in topics: Ceritinib & ALK inhibitor. The author has an hindex of 6, co-authored 10 publications receiving 904 citations.
Papers
More filters
Journal ArticleDOI
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean-Charles Soria,Daniel Shao-Weng Tan,Rita Chiari,Yi-Long Wu,Luis Paz-Ares,Juergen Wolf,Sarayut Lucien Geater,Sergey Orlov,Diego Cortinovis,Chong-Jen Yu,Maximillian Hochmair,Alexis B. Cortot,Chun-Ming Tsai,Denis Moro-Sibilot,Rosario Garcia Campelo,Tracey McCulloch,Paramita Sen,Margaret Dugan,Serafino Pantano,Fabrice Branle,Cristian Massacesi,Gilberto de Castro +21 more
TL;DR: First-line ceritinib showed a statistically significant and clinically meaningful improvement in progression-free survival versus chemotherapy in patients with advanced ALK-rearranged NSCLC.
Journal ArticleDOI
Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma
Eric Angevin,Jose A. Lopez-Martin,Chia-Chi Lin,Jürgen E. Gschwend,Andrea L. Harzstark,Daniel Castellano,Jean-Charles Soria,Paramita Sen,Julie Chang,Michael Shi,Andrea Kay,Bernard Escudier +11 more
TL;DR: Dovitinib was tolerable and showed antitumor activity at a maximum tolerated dose of 500 mg on a 5- days-on/2-days-off schedule in heavily pretreated RCC patients.
Journal ArticleDOI
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma
Matthew I. Milowsky,Christian Dittrich,Ignacio Duran,Satinder Jagdev,Frederick Millard,Christopher Sweeney,Dean F. Bajorin,Linda Cerbone,David I. Quinn,Walter M. Stadler,Jonathan E. Rosenberg,Melissa Lochheed,Paramita Sen,Matthew Squires,Michael Shi,Cora N. Sternberg +15 more
TL;DR: Although generally well tolerated, dovitinib has very limited single-agent activity in patients with previously treated advanced UC, regardless of FGFR3 mutation status.
Journal ArticleDOI
Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3.
Matthew I. Milowsky,Christian Dittrich,Ignacio Duran Martinez,Satinder Jagdev,Frederick Millard,Christopher Sweeney,Dean F. Bajorin,Linda Cerbone,Robert M. Dunn,Paramita Sen,Michael Shi,Andrea C. Kay,Matthew Squires,Cora N. Sternberg +13 more
TL;DR: Although there were difficulties in evaluating mutation status, dovitinib had limited single-agent activity in pts with advanced bladder cancer regardless of FGFR3 mutation status and the study was terminated.
Journal ArticleDOI
Bm-32ceritinib (ldk378) for treatment of patients with alk-rearranged (alk+) non-small cell lung cancer (nsclc) and brain metastases (bm) in the ascend-1 trial
Alice T. Shaw,Ranee Mehra,Daniel Shao-Weng Tan,Enriqueta Felip,Laura Q.M. Chow,D. Ross Camidge,Johan Vansteenkiste,Sunil Sharma,Tommaso De Pas,Gregory J. Riely,Benjamin Solomon,Juergen Wolf,Michael Thomas,Martin Schuler,Geoffrey Liu,Armando Santoro,Margarida Geraldes,Paramita Sen,Anthony J. Boral,A. Yovine,Dong Wan Kim +20 more
TL;DR: Ceritinib has clinically significant durable efficacy in patients with ALK+ NSCLC, including patients with BM, regardless of prior ALKi treatment, according to the phase I ASCEND-1 study.